A Comparison of Anti-cyclic Citrullinated Peptides (CCP3 and CCP3.1) Autoantibody Tests in Rheumatoid Arthritis

Overview

Journal Pract Lab Med

Specialty Biochemistry

Date 2024 Aug 20

PMID 39161944

Authors

Heather A Nelson

Dipanwita Banerjee

Camille L Novis

Kevin D Deane

Marie L Feser

Vijayalakshmi Nandakumar

Affiliations

Soon will be listed here.

Abstract

Background: Anti-citrullinated protein antibodies (ACPA) are a specific serological biomarker used in the diagnosis of rheumatoid arthritis (RA). In clinical practice ACPA can be identified using immunoassays targeting synthetic cyclic citrullinated peptides (CCP). The 3rd generation anti-CCP IgG antibody (CCP3) offers improved sensitivity compared to the earlier versions. Recently, CCP3.1, capable of detecting both IgG and IgA antibodies, was introduced to enhance sensitivity, especially in patients with early RA.

Methods: We assessed serum CCP3.1 against CCP3 in 331 subjects undergoing RA panel serology, comprising 136 patients with RA and 195 patients without RA. Sera were tested for anti-CCP IgG (CCP3) and anti-CCP IgG/IgA (CCP3.1) antibodies. Clinical performance of these tests was compared at manufacturer-suggested cutoffs. A separate set of 81 patients with a diagnosis of RA by 2010 criteria and whose samples were obtained from within 1-year of RA diagnosis was similarly assessed to evaluate assay performance in an independent clinical RA cohort.

Results: Overall diagnostic accuracy was similar; CCP3 had an area under the curve (AUC) of 0.88, CCP3.1 had an AUC of 0.89. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for CCP3 were 79 %, 91 %, 86 %, and 86 %, respectively. For CCP3.1, sensitivity was 78 %, specificity 93 %, PPV 89 %, NPV 86 %. Both assays demonstrated excellent agreement; positive percent agreement of 94 % and negative percent agreement of 99 %.

Conclusion: Our findings indicate comparable diagnostic accuracy between CCP3 and CCP3.1 assays in these clinical cohorts.

References

Whiting P, Smidt N, Sterne J, Harbord R, Burton A, Burke M . Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med. 2010; 152(7):456-64. DOI: 10.7326/0003-4819-152-7-201004060-00010. View

Schellekens G, Visser H, de Jong B, van den Hoogen F, Hazes J, Breedveld F . The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000; 43(1):155-63. DOI: 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3. View

Jaskowski T, Hill H, Russo K, Lakos G, Szekanecz Z, Teodorescu M . Relationship between rheumatoid factor isotypes and IgG anti-cyclic citrullinated peptide antibodies. J Rheumatol. 2010; 37(8):1582-8. DOI: 10.3899/jrheum.091236. View

Hanley J, McNeil B . A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983; 148(3):839-43. DOI: 10.1148/radiology.148.3.6878708. View

van der Linden M, van der Woude D, Ioan-Facsinay A, Levarht E, Stoeken-Rijsbergen G, Huizinga T . Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis.... Arthritis Rheum. 2009; 60(8):2232-41. DOI: 10.1002/art.24716. View

Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R . Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem. 2001; 47(6):1089-93. View

Lutteri L, Malaise M, Chapelle J . Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis. Clin Chim Acta. 2007; 386(1-2):76-81. DOI: 10.1016/j.cca.2007.08.002. View

Verpoort K, Jol-van der Zijde C, Papendrecht-van der Voort E, Ioan-Facsinay A, Drijfhout J, van Tol M . Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum. 2006; 54(12):3799-808. DOI: 10.1002/art.22279. View

Aggarwal R, Liao K, Nair R, Ringold S, Costenbader K . Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum. 2009; 61(11):1472-83. PMC: 2859449. DOI: 10.1002/art.24827. View

10.

Finckh A, Gilbert B, Hodkinson B, Bae S, Thomas R, Deane K . Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022; 18(10):591-602. DOI: 10.1038/s41584-022-00827-y. View

11.

Sieghart D, Konrad C, Swiniarski S, Haslacher H, Aletaha D, Steiner G . The diagnostic and prognostic value of IgG and IgA anti-citrullinated protein antibodies in patients with early rheumatoid arthritis. Front Immunol. 2023; 13:1096866. PMC: 9849943. DOI: 10.3389/fimmu.2022.1096866. View

12.

Taylor P, Gartemann J, Hsieh J, Creeden J . A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis. 2011; 2011:815038. PMC: 3170888. DOI: 10.4061/2011/815038. View

13.

Miettinen O, Nurminen M . Comparative analysis of two rates. Stat Med. 1985; 4(2):213-26. DOI: 10.1002/sim.4780040211. View

14.

Demoruelle M, Parish M, Derber L, Kolfenbach J, Hughes-Austin J, Weisman M . Performance of anti-cyclic citrullinated Peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease. Arthritis Rheum. 2013; 65(9):2243-52. PMC: 3776020. DOI: 10.1002/art.38017. View

15.

Kokkonen H, Mullazehi M, Berglin E, Hallmans G, Wadell G, Ronnelid J . Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther. 2011; 13(1):R13. PMC: 3241357. DOI: 10.1186/ar3237. View

16.

Sieghart D, Platzer A, Studenic P, Alasti F, Grundhuber M, Swiniarski S . Determination of Autoantibody Isotypes Increases the Sensitivity of Serodiagnostics in Rheumatoid Arthritis. Front Immunol. 2018; 9:876. PMC: 5929149. DOI: 10.3389/fimmu.2018.00876. View

17.

Debaugnies F, Servais G, Badot V, Noubouossie D, Willems D, Corazza F . Anti-cyclic citrullinated peptide antibodies: a comparison of different assays for the diagnosis of rheumatoid arthritis. Scand J Rheumatol. 2012; 42(2):108-14. DOI: 10.3109/03009742.2012.723746. View

18.

Correia M, Carvalho S, Fortuna J, Pereira M . Comparison of three anti-CCP antibody tests and rheumatoid factor in RA and control patients. Clin Rev Allergy Immunol. 2008; 34(1):21-5. DOI: 10.1007/s12016-007-8030-5. View

19.

van Gaalen F, Visser H, Huizinga T . A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis. 2005; 64(10):1510-2. PMC: 1755241. DOI: 10.1136/ard.2004.035089. View

20.

Svard A, Kastbom A, Reckner-Olsson A, Skogh T . Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project. Arthritis Res Ther. 2008; 10(4):R75. PMC: 2575621. DOI: 10.1186/ar2449. View